Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LNTH
STRONG BUYLantheus Holdings, Inc. · Healthcare · United States · $7.1B · Avg Vol: $105M/d
COMPANY DESCRIPTION
Lantheus Holdings, Inc. is a radiopharmaceutical company focused on developing, manufacturing, and commercializing innovative diagnostic and therapeutic products for medical imaging. It is a specialized leader in medical diagnostics, particularly in cardiology and oncology imaging agents, benefiting from proprietary technologies and regulatory approvals. Its pipeline of novel agents and established market presence provide a strong competitive moat in a high-barrier-to-entry market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 935.1M | 1.3B | 1.5B | 1.5B | 18.1% | 1.5B | 1.5B | 1.7B | 3.8% |
| EPS | 0.41 | 4.79 | 4.52 | 3.46 | 103.6% | 4.17 | 3.04 | 3.63 | 2.5% |
| Shares | 68.9M | 69.9M | 70.9M | 71.8M | +4.3% | 65.1M | — | — | — |
| Debt | 583.5M | 616.9M | 619.4M | 619.4M | 2.0% | 625.8M | — | — | — |
| Equity | 447.1M | 815.9M | 1.1B | 1.1B | 34.6% | — | — | — | — |
| Op CF | 281.8M | 305.3M | 544.8M | 390.1M | 11.5% | 407.7M | — | — | — |
| Inv CF | -276.5M | 5.9M | -226.0M | -627.2M | — | — | — | — | — |
| Fin CF | 311.7M | -13.1M | -118.5M | -316.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LNTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LNTH | Lantheus Holdings, Inc.(you) | $7.1B | 93 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.9B | 90 | STRONG BUY |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.5B | 87 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $16.9B | 94 | STRONG BUY |
| VIA.DE | Viatris Inc. | $19.0B | 88 | STRONG BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 96 | STRONG BUY |
| UTHR | United Therapeutics Corporation | $23.0B | 88 | STRONG BUY |
| ANIP | ANI Pharmaceuticals, Inc. | $1.9B | 97 | STRONG BUY |
| GTII.CN | Green Thumb Industries Inc. | $1.7B | 94 | STRONG BUY |
| PBH | Prestige Consumer Healthcare Inc. | $2.3B | 78 | BUY |
Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%